BACLOFEN

Product NDC
70934-918
11-digit product format
709340918
Labeler code
70934
Product ID
70934-918_f06e527b-159e-29d9-e053-2a95a90aab35
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
BACLOFEN
Dosage form
TABLET
Route
ORAL
Labeler
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
Application
ANDA209102
Marketing category
ANDA
Marketing start
2021-11-04
Marketing end
2024-05-31
Substance
BACLOFEN
Active strength
10 mg/1
Pharmacologic classes
GABA A Agonists [MoA], GABA B Agonists [MoA], gamma-Aminobutyric Acid-ergic Agonist [EPC]
NDC exclude flag
No
Listing certified through
0000-00-00
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct70934-918DDiscontinued by firm2026-07-31
excluded packagepackage70934-91870934-918-30DDiscontinued by firm2026-07-31
excluded packagepackage70934-91870934-918-60DDiscontinued by firm2026-07-31

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209102-001BACLOFENBACLOFEN5MGTABLET / ORALAB2017-11-28
A209102-002BACLOFENBACLOFEN10MGTABLET / ORALAB2017-11-28
A209102-003BACLOFENBACLOFEN20MGTABLET / ORALAB2017-11-28
A209102-004BACLOFENBACLOFEN15MGTABLET / ORALAB2024-02-05

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A209102-001AB
A209102-002AB
A209102-003AB
A209102-004AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BACLOFENBACLOFENRedpharm Drug53df4b4b-842e-9e3a-e063-6394a90a8a3d2026-06-10Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENREMEDYREPACK INC.e017a001-8cb1-4dd8-960e-c6d74005f57f2026-05-12Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENREMEDYREPACK INC.ac9b720f-b755-49f1-9850-efb26feadaeb2026-04-14Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENPD-Rx Pharmaceuticals, Inc.ee59a379-17d5-487f-b72f-a53e74744a702026-03-27Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENPD-Rx Pharmaceuticals, Inc.91175128-8285-4d04-89a9-219781be92602026-03-25Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENPD-Rx Pharmaceuticals, Inc.16266972-843e-4ea5-be1f-fb1b1588a5dc2026-03-25Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENPD-Rx Pharmaceuticals, Inc.0a1d09ac-94d5-45ef-92cc-bc261c2b2d752026-03-25Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENMajor Pharmaceuticals46f84504-ffc4-4be5-9598-c20a3f4210f42026-02-13Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENAdvagen Pharma Limited04dac0f6-cc6c-4959-9bca-a6e4a99690f32026-01-23Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENREMEDYREPACK INC.00c6c924-ddfd-4a75-afd7-f6561ff9abbc2026-01-21Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENAdvanced Rx of Tennessee, LLC459ec5f5-4f99-e917-e063-6294a90a23cd2025-12-18Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENSOLA Pharmaceuticals, LLC7b308b35-8c08-458d-860e-c78d057e82602025-12-08Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENProficient Rx LP0680301a-1649-46c4-b74e-ab03967945d02025-12-01Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENPD-Rx Pharmaceuticals, Inc.5cba5255-e5ad-48fd-8385-60e9ea6b64072025-10-09Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENREMEDYREPACK INC.4e2cd27d-91c7-4f15-96cc-3971769dbeaa2025-10-01Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENAsclemed USA, Inc.35bccefe-8d2e-85b5-e063-6394a90a58ca2025-08-13Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENA-S Medication Solutionseb690a49-b87b-433f-9afe-2966406fe00e2025-07-15Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENA-S Medication Solutionsaf0ade6c-9dd4-42d3-879e-4201fbe585ee2025-07-15Warnings, Adverse reactionsExact identifier
BACLOFENBACLOFENProficient Rx LP0243dd97-1d40-48f7-8853-76e046c605f22025-04-01Warnings, Adverse reactionsExact identifier
BaclofenBACLOFENDirect_Rx020632f4-5e8a-f4a0-e063-6294a90a63012025-01-28Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradua ly reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. b. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. c. Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. d. Stroke: Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug. e. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits. There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%). Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope. Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria. Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion. Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
70934-918-307093409183030 TABLET in 1 BOTTLE, PLASTIC (70934-918-30) 30 tablet2021-11-040000-00-00NoNoCurrent
70934-918-607093409186060 TABLET in 1 BOTTLE, PLASTIC (70934-918-60) 60 tablet2022-03-180000-00-00NoNoCurrent